Literature DB >> 22896611

Modulation of ribosomal frameshifting frequency and its effect on the replication of Rous sarcoma virus.

Emily I C Nikolic1, Louise M King, Marijana Vidakovic, Nerea Irigoyen, Ian Brierley.   

Abstract

Programmed -1 ribosomal frameshifting is widely used in the expression of RNA virus replicases and represents a potential target for antiviral intervention. There is interest in determining the extent to which frameshifting efficiency can be modulated before virus replication is compromised, and we have addressed this question using the alpharetrovirus Rous sarcoma virus (RSV) as a model system. In RSV, frameshifting is essential in the production of the Gag-Pol polyprotein from the overlapping gag and pol coding sequences. The frameshift signal is composed of two elements, a heptanucleotide slippery sequence and, just downstream, a stimulatory RNA structure that has been proposed to be an RNA pseudoknot. Point mutations were introduced into the frameshift signal of an infectious RSV clone, and virus replication was monitored following transfection and subsequent infection of susceptible cells. The introduced mutations were designed to generate a range of frameshifting efficiencies, yet with minimal impact on encoded amino acids. Our results reveal that point mutations leading to a 3-fold decrease in frameshifting efficiency noticeably reduce virus replication and that further reduction is severely inhibitory. In contrast, a 3-fold stimulation of frameshifting is well tolerated. These observations suggest that small-molecule inhibitors of frameshifting are likely to have potential as agents for antiviral intervention. During the course of this work, we were able to confirm, for the first time in vivo, that the RSV stimulatory RNA is indeed an RNA pseudoknot but that the pseudoknot per se is not absolutely required for virus viability.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896611      PMCID: PMC3486330          DOI: 10.1128/JVI.01846-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Complete nucleotide sequence of a highly infectious avian leukosis virus.

Authors:  E Bieth; J L Darlix
Journal:  Nucleic Acids Res       Date:  1992-01-25       Impact factor: 16.971

2.  Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication.

Authors:  Andreas Leiherer; Christine Ludwig; Ralf Wagner
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

3.  Proteolytic cleavage at the Gag-Pol junction in avian leukosis virus: differences in vitro and in vivo.

Authors:  L Stewart; V M Vogt
Journal:  Virology       Date:  1994-10       Impact factor: 3.616

4.  Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.

Authors:  M Shehu-Xhilaga; S M Crowe; J Mak
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors.

Authors:  S H Hughes; J J Greenhouse; C J Petropoulos; P Sutrave
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

6.  Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2-A resolution.

Authors:  M Jaskólski; M Miller; J K Rao; J Leis; A Wlodawer
Journal:  Biochemistry       Date:  1990-06-26       Impact factor: 3.162

7.  The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy.

Authors:  Preetha Biswas; Xi Jiang; Annmarie L Pacchia; Joseph P Dougherty; Stuart W Peltz
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon.

Authors:  Y Yoshinaka; I Katoh; T D Copeland; S Oroszlan
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  A region of the coronavirus infectious bronchitis virus 1a polyprotein encoding the 3C-like protease domain is subject to rapid turnover when expressed in rabbit reticulocyte lysate.

Authors:  K W Tibbles; I Brierley; D Cavanagh; T D Brown
Journal:  J Gen Virol       Date:  1995-12       Impact factor: 3.891

10.  Stimulation of ribosomal frameshifting by antisense LNA.

Authors:  Chien-Hung Yu; Mathieu H M Noteborn; René C L Olsthoorn
Journal:  Nucleic Acids Res       Date:  2010-08-06       Impact factor: 16.971

View more
  6 in total

Review 1.  Ribosomal frameshifting and transcriptional slippage: From genetic steganography and cryptography to adventitious use.

Authors:  John F Atkins; Gary Loughran; Pramod R Bhatt; Andrew E Firth; Pavel V Baranov
Journal:  Nucleic Acids Res       Date:  2016-07-19       Impact factor: 16.971

2.  Determinants of Moloney murine leukemia virus Gag-Pol and genomic RNA proportions.

Authors:  Silas F Johnson; John T Collins; Victoria M D'Souza; Alice Telesnitsky
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

3.  Modulation of stop codon read-through efficiency and its effect on the replication of murine leukemia virus.

Authors:  Eszter Csibra; Ian Brierley; Nerea Irigoyen
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

4.  Multiple Cis-acting elements modulate programmed -1 ribosomal frameshifting in Pea enation mosaic virus.

Authors:  Feng Gao; Anne E Simon
Journal:  Nucleic Acids Res       Date:  2015-11-17       Impact factor: 16.971

5.  High-throughput interrogation of programmed ribosomal frameshifting in human cells.

Authors:  Martin Mikl; Yitzhak Pilpel; Eran Segal
Journal:  Nat Commun       Date:  2020-06-16       Impact factor: 14.919

6.  Modulation of Viral Programmed Ribosomal Frameshifting and Stop Codon Readthrough by the Host Restriction Factor Shiftless.

Authors:  Sawsan Napthine; Chris H Hill; Holly C M Nugent; Ian Brierley
Journal:  Viruses       Date:  2021-06-25       Impact factor: 5.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.